Xu Hui, Jiang Xiao-Meng, Wu Ying, Li Yu-Mei, Zheng Yun-Wen, Ohkohchi Nobuhiro
Institute of Regenerative Medicine, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212001, China.
Department of Dermatology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212001, China.
AME Case Rep. 2020 Apr 30;4:14. doi: 10.21037/acr.2020.04.02. eCollection 2020.
Thrombopoietin (TPO) can improve liver regeneration and fibrosis. We report on a patient with liver cirrhosis who received treatment with TPO to improve liver function. An 82-year-old male had liver cirrhosis with ascites due to hepatitis C virus infection. The Child-Pugh classification was Child B. The patient received human recombinant TPO for 12 months. The platelet counts increased and were maintained at 60-80×10/L. The liver function improved, the ascites resolved, and the liver volume increased. These results indicate that the novel treatment with recombinant human TPO (rhTPO) may be effective for improving liver function in patients with liver cirrhosis.
血小板生成素（TPO）可促进肝再生并改善肝纤维化。我们报告了一名肝硬化患者接受TPO治疗以改善肝功能的情况。一名82岁男性因丙型肝炎病毒感染导致肝硬化并伴有腹水。Child-Pugh分级为B级。该患者接受人重组TPO治疗12个月。血小板计数增加并维持在60 - 80×10⁹/L。肝功能得到改善，腹水消退，肝脏体积增大。这些结果表明，重组人TPO（rhTPO）的新型治疗方法可能对改善肝硬化患者的肝功能有效。
